Sarcoidosis following alemtuzumab treatment for multiple sclerosis

被引：25

作者：

Willis, Mark D. ^{[1
,2
,3
]}

Hope-Gill, Ben ^{[4
]}

Flood-Page, Patrick ^{[5
]}

Joseph, Fady ^{[6
]}

Needham, Ed ^{[7
]}

Jones, Joanne ^{[7
]}

Coles, Alasdair ^{[7
]}

Robertson, Neil P. ^{[1
,2
,3
]}

机构：

[1] Cardiff Univ, Inst Psychol Med & Clin Neurosci, Heath Pk, Cardiff CF14 4XN, S Glam, Wales

[2] Univ Hosp Wales, Heath Pk, Cardiff CF14 4XN, S Glam, Wales

[3] Univ Hosp Wales, Dept Neurol, Cardiff, S Glam, Wales

[4] Univ Hosp Llandough, Dept Resp Med, Llandough, Wales

[5] Royal Gwent Hosp, Dept Resp Med, Newport, Gwent, Wales

[6] Royal Gwent Hosp, Dept Neurol, Newport, Gwent, Wales

[7] Addenbrookes Hosp, Dept Neurol, Cambridge, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷 / 13期

关键词：

Multiple sclerosis; alemtuzumab; IMMUNE RECONSTITUTION;

D O I：

10.1177/1352458518790391

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date, these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report three (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.

引用

页码：1779 / 1782

页数：4

共 8 条

[1] Alemtuzumab Treatment of Multiple Sclerosis
Coles, Alasdair F.
[J]. SEMINARS IN NEUROLOGY, 2013, 33 (01) : 66 - 73
[2] Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO
Gelfand, Jeffrey M.
Cotter, Jennifer
Klingman, Jeffrey
Huang, Eric J.
Cree, Bruce A. C.
[J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2014, 1 (03):
[3] Immune reconstitution inflammatory syndrome associated with pulmonary sarcoidosis in an HIV-infected patient: an immunohistochemical study
Peixoto de Miranda, Erique Jose
Munhoz Leite, Olavo Henrique
Seixas Duarte, Maria Irma
[J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 15 (06) : 601 - 606
[4] Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Saarela, Mika
Senthil, Keerthi
Jones, Joanne
Tienari, Pentti J.
Soilu-Hanninen, Merja
Airas, Laura
Coles, Alasdair
Saarinen, Jukka T.
[J]. NEUROLOGY, 2018, 90 (18) : 849 - 851
[5] The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution
Thachil, Jecko
Jadhav, Vittal
Gautam, Manish
Mckew, Steve
Arumainathan, Arvind
Collins, Daniel
Smyth, Colin
Harper, Janice
Pettitt, Andrew
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 559 - 560
[6] Sarcoidosis
Valeyre, Dominique
Prasse, Antje
Nunes, Hilario
Uzunhan, Yurdagul
Brillet, Pierre-Yves
Mueller-Quernheim, Joachim
[J]. LANCET, 2014, 383 (9923) : 1155 - 1167
[7] Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
Willis, M. D.
Harding, K. E.
Pickersgill, T. P.
Wardle, M.
Pearson, O. R.
Scolding, N. J.
Smee, J.
Robertson, N. P.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (09) : 1215 - 1223
[8] Alemtuzumab for Multiple Sclerosis
Willis, Mark D.
Robertson, Neil P.
[J]. CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (09)

← 1 →